Abstract: Immunological checkpoint inhibitors have become one of the major treatment options for patients with advanced non-small cell lung cancer (NSCLC). Despite patients with NSCLC show the superiority of standard chemotherapy in different disease settings, the response rate is still low in patients with high macromolecule selection for chemotherapy tolerance and gene mutation. This is related to the complexity and dyna-mics of known limited biomarkers and tumor microenvironment. Different methods of tumor cells to evade the immune system used to lay the foundation for the new combination strategy. Combination therapy not only improves the efficacy of treatment, but also makes the objective response rate improved significantly.

Key words: Carcinoma, non-small-cell lung, Immunosuppressive agents, Therapy